Synvolux Therapeutics B.V. is a privately held biotech company dedicated to the development, production and commercialisation of new therapies using its SAINT technology: an unique, safe and highly efficacious delivery technology for macromolecules (DNA, RNA, proteins and others). Synvolux sells its products for R&D use.
Synvolux Therapeutics uses its SAINT technology for the delivery of drugs based on synthetic, non-toxic chemical compounds. We develop novel products with designed features to meet the needs of our drug development partners and our own programs. Synvolux' compounds promise to improve the potential of DNA mediated therapy, circumventing the dangers of viral delivery and the inefficiency of other approaches.
Contact:
L.J. Zielstraweg 1
9713 GX
Gronigen
The Netherlands
Tel: +31 50 311 8115
Fax: +31 50 311 8995
Website: www.synvolux.nl